With Alkermes’ Transition Well Under Way, Commercial Expansion Is Next
As Alkermes advances its proprietary pipeline, the company is beginning to build its commercial organization ahead of what will be the launch of its first wholly owned drug since it took the marketing reins with Vivitrol in 2008.
You may also be interested in...
BIO 2014 Tuesday Round-Up: AstraZeneca Looking Forward, Not Back
With Day 2 of the BIO convention in San Diego in full swing, major deals, academic partnerships and hot pipelines take center stage – as long as they can be discussed in the World Cup Lounge.
Deals Of The Week Looks At 2014 Takeout Targets
The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.
Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.